These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38429321)

  • 1. G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage.
    Pena N; Richbourg T; Gonzalez-Hunt CP; Qi R; Wren P; Barlow C; Shanks NF; Carlisle HJ; Sanders LH
    NPJ Parkinsons Dis; 2024 Mar; 10(1):49. PubMed ID: 38429321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
    Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A blood-based marker of mitochondrial DNA damage in Parkinson's disease.
    Qi R; Sammler E; Gonzalez-Hunt CP; Barraza I; Pena N; Rouanet JP; Naaldijk Y; Goodson S; Fuzzati M; Blandini F; Erickson KI; Weinstein AM; Lutz MW; Kwok JB; Halliday GM; Dzamko N; Padmanabhan S; Alcalay RN; Waters C; Hogarth P; Simuni T; Smith D; Marras C; Tonelli F; Alessi DR; West AB; Shiva S; Hilfiker S; Sanders LH
    Sci Transl Med; 2023 Aug; 15(711):eabo1557. PubMed ID: 37647388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.
    Gonzalez-Hunt CP; Thacker EA; Toste CM; Boularand S; Deprets S; Dubois L; Sanders LH
    Sci Rep; 2020 Oct; 10(1):17293. PubMed ID: 33057100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial Mechanisms of LRRK2 G2019S Penetrance.
    Delcambre S; Ghelfi J; Ouzren N; Grandmougin L; Delbrouck C; Seibler P; Wasner K; Aasly JO; Klein C; Trinh J; Pereira SL; Grünewald A
    Front Neurol; 2020; 11():881. PubMed ID: 32982917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
    Lubben N; Brynildsen JK; Webb CM; Li HL; Leyns CEG; Changolkar L; Zhang B; Meymand ES; O'Reilly M; Madaj Z; DeWeerd D; Fell MJ; Lee VMY; Bassett DS; Henderson MX
    Transl Neurodegener; 2024 Mar; 13(1):13. PubMed ID: 38438877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
    Su YC; Qi X
    Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.
    Novello S; Mercatelli D; Albanese F; Domenicale C; Brugnoli A; D'Aversa E; Vantaggiato S; Dovero S; Murtaj V; Presotto L; Borgatti M; Shimshek DR; Bezard E; Moresco RM; Belloli S; Morari M
    Neurobiol Dis; 2022 Jan; 162():105579. PubMed ID: 34871735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.
    Kelly K; Wang S; Boddu R; Liu Z; Moukha-Chafiq O; Augelli-Szafran C; West AB
    Exp Neurol; 2018 Nov; 309():1-13. PubMed ID: 30048714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues.
    Iannotta L; Biosa A; Kluss JH; Tombesi G; Kaganovich A; Cogo S; Plotegher N; Civiero L; Lobbestael E; Baekelandt V; Cookson MR; Greggio E
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.
    Longo F; Russo I; Shimshek DR; Greggio E; Morari M
    Neurobiol Dis; 2014 Nov; 71():62-73. PubMed ID: 25107341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.
    Bonello F; Hassoun SM; Mouton-Liger F; Shin YS; Muscat A; Tesson C; Lesage S; Beart PM; Brice A; Krupp J; Corvol JC; Corti O
    Hum Mol Genet; 2019 May; 28(10):1645-1660. PubMed ID: 30629163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.
    Sanders LH; Laganière J; Cooper O; Mak SK; Vu BJ; Huang YA; Paschon DE; Vangipuram M; Sundararajan R; Urnov FD; Langston JW; Gregory PD; Zhang HS; Greenamyre JT; Isacson O; Schüle B
    Neurobiol Dis; 2014 Feb; 62():381-6. PubMed ID: 24148854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
    Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
    Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity.
    Garofalo AW; Schwarz J; Zobel K; Beato C; Bernardi S; Budassi F; Caberlotto L; Gao P; Griffante C; Liu X; Migliore M; Qiao F; Sabbatini FM; Sava A; Zhang M; Carlisle HJ
    Bioorg Med Chem Lett; 2023 Oct; 95():129487. PubMed ID: 37734423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.